PHAT

Phathom Pharmaceuticals, Inc. (PHAT) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on gastrointestinal diseases, primarily commercializing VOQUEZNA (vonoprazan) for Erosive GERD, Non-Erosive GERD, and H. pylori infection. The company operates as a single reportable segment and is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net product revenue increased by 104.8% year-over-year, driven by continued commercial execution and prescription volume growth for VOQUEZNA products.
• Expense Reduction: Total operating expenses decreased by 40.4% to $61.8 million. Selling, general, and administrative (SG&A) expenses dropped significantly by $40.5 million, primarily due to a $36.9 million reduction in advertising and promotional expenses following a May 2025 restructuring plan.
• Debt Restructuring: On February 25, 2026, the company entered into a Fifth Amendment to its Loan Agreement with Hercules Capital. This involved a new $175 million term loan advance used to repay existing obligations, extending the maturity date to February 2029, and eliminating the payment-in-kind (PIK) interest component.
• Capital Raise: In January 2026, the company completed an underwritten public offering, raising net proceeds of approximately $122.0 million through the sale of common stock and pre-funded warrants.
• Loss Narrowing: Net loss improved significantly from $94.3 million in Q1 2025 to $30.4 million in Q1 2026, reflecting revenue growth and cost containment.

Guidance, Outlook, and Risks

• Profitability Outlook: Management anticipates achieving operating profitability (excluding stock-based compensation) beginning in the third quarter of 2026.
• Liquidity: As of March 31, 2026, the company holds $180.9 million in cash. Management believes existing cash and anticipated revenues are sufficient to fund operations for at least the next twelve months.
• Debt Covenants: The company is currently in compliance with all financial covenants under its Loan Agreement and Revenue Interest Financing Agreement. Key covenants include maintaining minimum cash balances relative to outstanding principal and meeting specific revenue performance thresholds.
• Risks:
  • Supply Chain: Potential disruption in the supply of clarithromycin tablets (a component of VOQUEZNA TRIPLE PAK) remains a monitored risk, though no near-term disruption is currently anticipated.
  • Revenue Interest Financing: The company owes royalties to investors equal to 10% of net sales until investors receive 200% of the investment amount. Future interest expense is sensitive to revenue projections.
  • Customer Concentration: Three customers accounted for 70% of product sales in Q1 2026.

Key Facts for Investor Verification

• Debt Structure: Verify the terms of the new $175 million Hercules term loan, specifically the floating interest rate (Prime + 3.10% or 9.85%, whichever is greater) and the final payment fee structure (ranging from 1.25% to 3.5% based on repayment timing).
• Revenue Interest Liability: Confirm the carrying value of the $380.9 million revenue interest financing liability and the impact of actual sales versus projections on future interest accretion.
• Restructuring Impact: Assess the sustainability of the reduced SG&A spend ($54.0 million in Q1 2026 vs. $94.5 million in Q1 2025) and whether further cost reductions are necessary to meet the Q3 2026 profitability target.
• Supply Agreement: Review the amended supply agreement with Sandoz regarding minimum purchase obligations and the status of clarithromycin supply stability.
• Equity Dilution: Note the issuance of 6.9 million shares and pre-funded warrants in January 2026 and the remaining availability of the $150 million ATM facility.